AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Seagen Inc (NASDAQ:SGEN)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | -- |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 228.960/124.710 |
| EBITDA (in USD) | -677.358M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -4.00 |
| Total Assets (in USD) | 3674.532M |
|---|---|
| Total Liabilities (in USD) | 870.713M |
| Revenue TTM (in USD) | 2300.351M |
| Cash (in USD) | 319.94M |
| Market Cap (in USD) | 43,154.776 M |
| Revenue Per Share TTM | 12.290 |
| Gross Profit TTM (in USD) | 207.993M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Seagen Inc
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
Employees: 3256
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Todd E. Simpson | Chief Financial Officer | 1961 |
| 2. | Ms. Jean I. Liu J.D., M.S. | Chief Legal Officer | 1968 |
| 3. | Mr. Charles R. Romp | Exec. VP of Commercial U.S. | 1968 |
| 4. | Dr. Roger D. Dansey M.D. | Pres of R&D | 1956 |
| 5. | Mr. David R. Epstein B.Sc., M.B.A. | CEO & Director | 1962 |
| 6. | Dr. Vaughn B. Himes Ph.D. | Chief Technical Officer | 1961 |
| 7. | Peggy Pinkston | Sr. VP of Investor Relations | NA |
| 8. | Mr. David Caouette | VP of Corp. Communications | NA |
| 9. | Mr. Matt Skelton | VP of Marketing | NA |
| 10. | Mr. Christopher P. Pawlowicz | Exec. VP of HR | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.080 0.182% | 43.94 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.990 4.737% | 44 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.115 0.026% | 440.02 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.660 0.108% | 613.11 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -602.315M | -675.705M | 615.701M | -158.65M | -246.346M |
| Minority Interest | - | - | - | - | - |
| Net Income | -610.308M | -674.471M | 613.67M | -63.241M | -222.693M |
| Selling General Administrative | 820.963M | 716.19M | 533.835M | 373.932M | 261.096M |
| Gross Profit | 1552.354M | 1262.806M | 1957.816M | 872.761M | 566.407M |
| Reconciled Depreciation | 82.158M | 78.626M | 63.384M | 33.514M | 26.032M |
| Ebit | -612.97M | -682.056M | 596.852M | -220.545M | -299.682M |
| Ebitda | -623.625M | -688.407M | 578.003M | -282.44M | -273.65M |
| Depreciation And Amortization | -10.655M | -6.351M | -18.849M | -61.895M | 26.032M |
| Operating Income | -612.97M | -682.056M | 596.852M | -220.545M | -259.998M |
| Other Operating Expenses | 2575.382M | 2256.427M | 1578.684M | 1137.258M | 914.698M |
| Interest Expense | -103.468M | 91.328M | 101.082M | 0M | 0M |
| Tax Provision | 7.993M | -1.234M | 2.031M | 0M | -23.653M |
| Interest Income | - | - | - | 61.895M | 13.652M |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | 7.993M | -1.234M | 2.031M | -95.409M | -23.653M |
| Total Revenue | 1962.412M | 1574.371M | 2175.536M | 916.713M | 654.7M |
| Total Operating Expenses | 2165.324M | 1944.862M | 1360.964M | 1093.306M | 826.405M |
| Cost Of Revenue | 410.058M | 311.565M | 217.72M | 43.952M | 88.293M |
| Total Other Income Expense Net | 10.655M | 6.351M | 18.849M | 61.895M | 13.652M |
| Net Income From Continuing Ops | -610.308M | -674.471M | 613.67M | -158.65M | -222.693M |
| Net Income Applicable To Common Shares | -610.308M | -674.471M | 613.67M | -158.65M | -222.693M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 3674.532M | 3719.604M | 4000.906M | 2205.866M | 1503.329M |
| Intangible Assets | 237.516M | 260.593M | 283.68M | 300M | 300.04M |
| Other Current Assets | 138.34M | 119.239M | 61.84M | 43.653M | 43.403M |
| Total Liab | 870.713M | 654.465M | 512.806M | 329.579M | 229.386M |
| Total Stockholder Equity | 2803.819M | 3065.139M | 3488.1M | 1876.287M | 1273.943M |
| Other Current Liab | 610.553M | 454.03M | 30.13M | 197.62M | 147.293M |
| Common Stock | 0.187M | 0.183M | 0.181M | 0.172M | 0.16M |
| Capital Stock | 0.187M | 0.183M | 0.181M | 0.172M | 0.16M |
| Retained Earnings | -2154.347M | -1544.039M | -869.568M | -1483.238M | -1324.588M |
| Good Will | 274.671M | 274.671M | 274.671M | 274.671M | 274.671M |
| Other Assets | 61.041M | 47.184M | 183.471M | 312.614M | 308.237M |
| Cash | 319.94M | 424.834M | 558.424M | 274.562M | 78.186M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 818.404M | 568.854M | 388.138M | 259.357M | 191.472M |
| Current Deferred Revenue | - | - | 267.192M | - | 33.6M |
| Net Debt | -276.466M | -368.169M | -483.791M | -197.51M | -78.186M |
| Short Term Debt | - | - | 12.749M | 9.445M | -33.6M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 43.474M | 56.665M | 74.633M | 77.052M | - |
| Other Stockholder Equity | 4954.469M | 4607.816M | 4356.922M | 3359.124M | 2598.411M |
| Property Plant Equipment | 248.179M | 210.073M | 196.7M | 155.491M | 103.82M |
| Total Current Assets | 1735.07M | 2160.036M | 2660.25M | 868.338M | 459.866M |
| Long Term Investments | - | 0M | 100.83M | 57.283M | 49.194M |
| Short Term Investments | 1415.13M | 1735.202M | 2000.996M | 536.493M | 332.486M |
| Net Receivables | 501.912M | 389.256M | 324.988M | 236.001M | 146.281M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 427.211M | 200.663M | 116.136M | 85.932M | 53.239M |
| Accounts Payable | 207.851M | 114.824M | 78.067M | 52.292M | 44.179M |
| Accumulated Other Comprehensive Income | 3.51M | 1.179M | 0.565M | 0.229M | -0.04M |
| Non Currrent Assets Other | 1132.358M | 756.342M | 1340.656M | 1337.528M | 1043.463M |
| Non Current Assets Total | 1939.462M | 1559.568M | 1340.656M | 1337.528M | 1043.463M |
| Capital Lease Obligations | 43.474M | 56.665M | 74.633M | 77.052M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 325.736M | 341.214M | -1336.603M | -206.976M | 26.74M |
| Total Cashflows From Investing Activities | 228.237M | 288.884M | -1419.012M | -277.729M | -592.63M |
| Total Cash From Financing Activities | 125.36M | 77.779M | 846.108M | 637.842M | 713.407M |
| Net Income | -610.308M | -674.471M | 613.67M | -158.65M | -222.693M |
| Change In Cash | -101.348M | -133.59M | 283.862M | 196.376M | -82.759M |
| Begin Period Cash Flow | 424.834M | 558.424M | 274.562M | 78.186M | 160.945M |
| End Period Cash Flow | 323.486M | 424.834M | 558.424M | 274.562M | 78.186M |
| Total Cash From Operating Activities | -453.751M | -499.007M | 856.568M | -163.737M | -203.536M |
| Depreciation | 82.158M | 78.626M | 63.384M | 33.514M | 26.032M |
| Other Cashflows From Investing Activities | -20.159M | -20.159M | -20.159M | -206.976M | -598.151M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -226.548M | -84.527M | -30.204M | -32.693M | 6.739M |
| Sale Purchase Of Stock | 125.36M | 77.779M | 846.108M | 637.842M | 713.407M |
| Other Cashflows From Financing Activities | 228.237M | 77.779M | 96.258M | 89.151M | 55.165M |
| Capital Expenditures | 77.34M | 52.33M | 82.409M | 70.753M | 21.219M |
| Change In Working Capital | -150.54M | -88.016M | 42.86M | -112.763M | -52.217M |
| Other Non Cash Items | 3.089M | 11.189M | -8.526M | -53.187M | -9.866M |
| Free Cash Flow | -531.091M | -551.337M | 774.159M | -234.49M | -224.755M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 4411389 |
| 2. | Invesco QQQ Trust | 2 years ago | 3305259 |
| 3. | Vanguard Mid Cap Index Institutional | 2 years ago | 3199926 |
| 4. | Vanguard Capital Opportunity Inv | 2 years ago | 2384545 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 2034071 |
| 6. | American Funds Growth Fund of Amer A | 2 years ago | 1674223 |
| 7. | Capital Group Growth Fnd of Amer Comp | 2 years ago | 1674223 |
| 8. | PRIMECAP Odyssey Aggressive Growth | 2 years ago | 1488013 |
| 9. | Capital Group New Perspective Comp | 2 years ago | 1483684 |
| 10. | American Funds New Perspective A | 2 years ago | 1483684 |
| 11. | BlackRock Event Driven Equity Instl | 2 years ago | 1467540 |
| 12. | iShares Biotechnology ETF | 2 years ago | 1275771 |
| 13. | Vanguard PRIMECAP Inv | 2 years ago | 1252675 |
| 14. | Vanguard Growth Index Investor | 2 years ago | 1240284 |
| 15. | Vanguard Mid-Cap Growth ETF | 2 years ago | 979335 |
| 16. | PRIMECAP Odyssey Growth | 2 years ago | 936250 |
| 17. | iShares MSCI USA Min Vol Factor ETF | 2 years ago | 831985 |
| 18. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 807946 |
| 19. | The Merger Fund A | 2 years ago | 797684 |
| 20. | Fidelity® Extended Market Index | 2 years ago | 749057 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Baker Bros Advisors LP | 2 years ago | 44554162 |
| 2. | Vanguard Group Inc | 2 years ago | 13321042 |
| 3. | Pentwater Capital Management LP | 2 years ago | 12880000 |
| 4. | BlackRock Inc | 2 years ago | 12051745 |
| 5. | PRIMECAP Management Company | 2 years ago | 6261798 |
| 6. | State Street Corporation | 2 years ago | 3359408 |
| 7. | Millennium Management LLC | 2 years ago | 3065700 |
| 8. | Citadel Advisors Llc | 2 years ago | 2428418 |
| 9. | Capital World Investors | 2 years ago | 2359715 |
| 10. | Balyasny Asset Management LLC | 2 years ago | 2278686 |
| 11. | JPMorgan Chase & Co | 2 years ago | 2255659 |
| 12. | Geode Capital Management, LLC | 2 years ago | 2121808 |
| 13. | Capital Research & Mgmt Co - Division 3 | 2 years ago | 1835398 |
| 14. | Barclays PLC | 2 years ago | 1779070 |
| 15. | venBio Select Advisor LLC | 2 years ago | 1759606 |
| 16. | Tudor Investment Corp Et AL | 2 years ago | 1171324 |
| 17. | Hudson Bay Capital Management LP | 2 years ago | 1139422 |
| 18. | Test Hedge Fund Mgmt | 2 years ago | 1134501 |
| 19. | PSquared Asset Management AG | 2 years ago | 1050645 |
| 20. | FMR Inc | 2 years ago | 1043155 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...